[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The University of New South Wales\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":158},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,72,101,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100585168","the-effect-of-01-topical-ciclosporin-a-for-12-weeks-on-the-eye-surface-immune-cells-in-dry-eyes-100585168",false,"NCT06898853","The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes","The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Ocular Surface Innate and Adaptive Immune Response in Dry Eye Disease","Inclusion Criteria:\n\n1. 18 years of age and above\n2. Participants should meet any two of the following DED diagnostic criteria: i) ocular surface disease index score of ≥23 and ii) Oxford staining score of ≥1 iii) Tear meniscus height \\\u003C 0.2 mm.\n\nExclusion Criteria:\n\n1. Participants currently using or with previous use of steroids, ciclosporin, lifitegrast or any anti-inflammatory eye drops in the last 6 months.\n2. Participants with systemic CsA or tacrolimus\n3. Known hypersensitivity or contraindication to the study medication or any of its ingredients.\n4. Active intraocular inflammation.\n5. Contact lens wear or the use of contact lenses in the last 4 weeks.\n6. Active eye infections or history of critical illness.\n7. DED secondary to Steven-Johnson syndrome and cicatricial conjunctival disease.\n8. Participants with other ocular co-morbidities and medications for glaucoma.\n9. Participants with previous history of ocular surgery in the past 6 months.\n10. Any other active or inactive systemic condition, structural abnormality such as eyelid malposition's that in the judgment of the investigator could confound study assessments or limit compliance.\n11. Pregnant\u002Fbreastfeeding women","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","Dry eye disease (DED) is a common, long-lasting condition that affects the surface of the eye. It happens when there's a problem with tear production or quality, which can lead to inflammation and discomfort. The immune system plays a big role in how DED develops and continues.\n\nResearchers have found that in people with DED, there are more immune cells and inflammatory substances in the tears and on the eye's surface. This includes various types of immune cells, like T cells and dendritic cells, which are part of the body's defense system.\n\nThe first treatment for DED is usually artificial tears, but because the condition is chronic and can flare up, clinicians often use anti-inflammatory treatments too. One such treatment is cyclosporine A (CsA), which comes as eye drops. CsA works by reducing inflammation and affects how immune cells behave.\n\nResearchers can study the immune cells on the eye's surface using a special microscopy technique called in vivo confocal microscopy (IVCM). A newer version of this method, called functional IVCM (Fun-IVCM), allows researchers to watch how these cells move and behave over time.\n\nIn the current study, researchers want to compare 0.1% CsA with a lubricating eye drop to see how they affect the immune cells on the eye's surface. The researchers will use Fun-IVCM to look at the number, shape, and movement of immune cells of the eye. The researchers will also collect samples from the eye's surface and tears to measure various markers of inflammation.\n\nThe goal is to better understand how CsA works in treating DED by directly observing its effects on the immune response in the eye, which is unexplored. This could help improve treatments for people suffering from this condition and expand the use of CsA in DED.",[26],"Dry Eye Disease (DED)","RECRUITING","2026-04-28",{"date":30,"type":31},"2026-05-05","ACTUAL",{"date":33,"type":31},"2025-06-01",{"date":35,"type":20},"2026-12-30",{"name":37,"class":38},"The University of New South Wales","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":39},"100597340","steps-against-the-burden-of-parkinsons-disease-100597340","NCT07057219","Steps Against the Burden of Parkinson's Disease","StepuP: Steps Against the Burden of Parkinson's Disease","StepuP","Inclusion Criteria:\n\n1. Diagnosis of PD according to the MDS Criteria\n2. Hoehn and Yahr stages I to III;\n3. Movement Disorder Society-sponsored version of the Unified Parkinson Disease Rating Scale (MDS-UPDRS) gait sub-score of 1 or more\n4. Signed informed consent to participation\n\nExclusion Criteria:\n\n* Any known general health condition likely to interfere with or to pose a contraindication to non-medically supervised physical exercise.\n* Moderate or severe depression (BDI-II ≥18)\n* Cognitive impairment which may preclude the possibility to provide a fully informed consent to enrolment.\n* Linguistic comprehension capacity less than 75% in ordinary conversation\n* Severe psychiatric comorbidity which may interfere with compliance to the study protocol\n* History of or current status of substance dependency\n* Unable to walk less than 1 floor\n* Thoracic pain in the last 4 weeks\n* Currently enrolled in other interventional studies\n* Implanted Deep Brain Stimulation device",{"count":49,"type":20},42,[23],"Parkinson's Disease Treadmill Training RCT Summary\n\nParkinson's disease (PD) affects over 10 million people globally. Despite optimal pharmacological treatment, approximately 70% of individuals experience unstable gait and falls, leading to loss of confidence, social isolation, fractures, and frequent hospitalisations. Treadmill training-especially when augmented by mechanical or virtual-reality perturbations-has shown promise in improving gait and reducing fall risk. However, the mechanisms underlying these benefits remain poorly understood, limiting the ability to personalise interventions effectively.\n\nThis randomised controlled trial (RCT) forms part of the broader Steps Against the Burden of Parkinson's Disease project (CT-IDs: 6ef2e427b002, 6ef2e427b003, 6ef2e427b004), comprising three harmonised but independently conducted RCTs. All sites follow a shared core protocol, allowing for pooled data analysis while preserving site-specific perturbation adaptations. Findings from this trial will be reported both independently and as part of the combined dataset.\n\nIn this trial, participants with PD will undergo 12 sessions of treadmill training, with or without virtual reality and perturbation-based adaptations. Assessments will be conducted at baseline, post-training, and follow-up. The intervention aims to enhance gait through improved sensorimotor integration and balance control. During the follow-up period, a smartphoneapp \"Walking Tall\" will be used to encourage continued exercises and long-term retention of training effects.\n\nBiomechanical analyses will focus on changes in foot placement control. Neurophysiological outcomes will be examined using EEG and EMG, targeting reductions in beta-band EEG power and enhanced EEG-EMG coherence as markers of improved gait stability.\n\nRecognising that laboratory-based improvements may not always translate to daily life, this study will also investigate gait self-efficacy as a potential moderator of transfer. Remote monitoring tools will capture real-world mobility outcomes over a week. Machine learning techniques will be employed to identify factors differentiating those who improve in both settings from those who do not. These insights will inform the development of personalised interventions capable of translating training effects into meaningful real-life outcomes.",[53],"Parkinson Disease (PD)",[55,56,57,58,59,60,61,62,63],"EEG","EMG","perturbation","VR","real-world gait","wearable device","gait","balance","falls","2025-07-13",{"date":66,"type":31},"2025-07-17",{"date":68,"type":31},"2025-07-09",{"date":70,"type":20},"2026-11-30",{"name":37,"class":38},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":39},"100561007","phase-2-lace-lactobacillus-paracasei-lpb27-on-early-childhood-eczema-100561007","NCT06584552","LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema)","Lactobacillus Paracasei LPB27 On Early Childhood Eczema","Inclusion Criteria:\n\n* Age: 3 months to 3 years old\n* Diagnosis: Eczema (atopic dermatitis) diagnosed clinically by a paediatric dermatologist or immunologist.\n* Severity: Investigator Global Assessment for Atopic Dermatitis (IGA) severity of 1-3 (almost clear, mild, moderate) and a SCORAD score greater than 8.7.\n* Willingness and ability of the subject to comply with the protocol requirements.\n\nExclusion Criteria:\n\n* Patients on systemic immunosuppression and\u002For biologic agents (participants who start systemic immunosuppression and\u002For biologic agents mid-way through the study will be considered to have not achieved treatment success and will be withdrawn, regardless of their SCORAD index scores).\n* Mothers who are breastfeeding and on probiotics but not willing to stop probiotics.\n* Child already on probiotics and parents not willing to stop during the entire study period (washout period of 4 weeks; including formulas that contains probiotics).\n* Eczema complicated by active skin infection e.g. impetigo\u002Fcellulitis\u002F eczema herpeticum (can be considered once active infection resolved).\n* Child currently on oral or IV antibiotics (washout period of 4 weeks allowable once antibiotics completed). Participants who require antibiotics after being enrolled in the study may continue on the study as usual.\n* Immunodeficient disorders.\n* Chronic disorder involving the gastrointestinal tract (e.g., inflammatory bowel disease, short gut syndrome, cystic fibrosis).\n* Known hypersensitivity to components contained in study product.","3 Months","3 Years",{"count":82,"type":20},100,[84],"PHASE2","The LaCE study is a double-blind, randomised, placebo-controlled trial examining the effectiveness of the probiotic Lactobacillus paracasei LPB27 in treating eczema in young children.",[87,88],"Eczema","Allergy",[90,91,92],"Immunology","Microbiome","Paediatrics","2025-05-28",{"date":95,"type":31},"2025-06-03",{"date":97,"type":31},"2024-11-15",{"date":99,"type":20},"2026-09",{"name":37,"class":38},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100522016","precision-care-initiative-integrating-precision-oncology-into-clinical-programs-100522016","NCT06077110","Precision Care Initiative: Integrating Precision Oncology Into Clinical Programs","Developing a Novel Precision Medicine Clinic to Drive Integration of Research Into Routine Healthcare: Precision Care Initiative","Inclusion Criteria:\n\n* have been referred to the Precision Care Clinic at POWH\n* speak English\n* are aged 18 years or over\n* are able to provide informed consent\n\nExclusion Criteria:\n\n* aged under 18 years\n* non-English speaking\n* are unable to provide informed consent",{"count":109,"type":20},300,[23],"The purpose of this study is to drive integration of precision medicine into routine oncology healthcare. It is hoped that this research will not only optimise the newly established Precision Care Clinic within the Prince of Wales Hospital, but also prime it for use within other health care sites. The multidisciplinary team will work to achieve the following three objectives:\n\n1. Co-design a Precision Care Clinic, its implementation platform and suite of outcome measures (Phase 1)\n2. Test the implementation-, service-, clinical, and cost-effectiveness of a Precision Care Clinic (Phase 2)\n3. Develop and pilot test a Precision Care scale-up model and toolkit (Phase 3)\n\nA mixed-methods approach will be used to develop and evaluate an implementation platform to support the integration of precision medicine into the routine oncology setting at a single hospital site. In the first study phase, interviews and focus-groups will be used to develop the implementation platform, which involves a co-designed model of care supported by a Learning Health System. A Type II Hybrid effectiveness-implementation trial design will then be used to test the implementation, clinical, and cost-effectiveness of this novel model of care (phase 2). A combination of patient surveys and interviews will be used to measure patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs); stakeholder and patient interviews, surveys and focus-groups will be used to measure implementation outcomes; and cost data will be collected to inform an economic evaluation. These data will be collected at various stages of implementation to evaluate the effectiveness of the model of care over time. In the final study phase (phase 3), a scale-up model will be developed to support implementation of the new model of care across a wider range of clinical contexts. (Phase 3 will be detailed in a separate ethics amendment)\n\nIt is hoped that this research will not only optimise the newly established model of care within The Prince of Wales Hospital, but also prime it for use within other health care sites.",[113],"Cancer",[115,116],"precision medicine","oncology","NOT_YET_RECRUITING","2025-03-24",{"date":120,"type":31},"2025-03-28",{"date":122,"type":20},"2025-05",{"date":124,"type":20},"2027-03",{"name":37,"class":38},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":138,"studyType":139,"phases":4,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":5},"100525246","multicenter-evaluation-of-near-vision-and-outdoor-time-in-kids-study-100525246","NCT06119243","Multicenter Evaluation of Near Vision and Outdoor Time in Kids Study","Multicenter Study of Near Vision Behavior and Outdoor Time in Children Undergoing Myopia Control","MENOK","Inclusion Criteria:\n\n1. Aged 6 to below 14 years old\n2. Spherical equivalent myopic refractive error greater than -0.50 D\n3. Best corrected logMAR visual acuity of 0.1 or better in each eye for 6- to 14-year-old children, and 0.2 logMAR or better than in each eye for 4 and 5-year-old children (adjusted for age-related expectations)\n4. Good ocular and general health that would not preclude them from myopia control\n5. Competent enough in English to fully understand the participant information and consent form\n6. Willing to undergo treatment to slow myopia progression for one year\n\nExclusion Criteria:\n\n1. Strabismus at distance or near, or amblyopia\n2. Systemic or ocular conditions that may affect contact lens use (e.g. severe allergy) or refractive development (e.g. ptosis)\n3. Previous history of ocular surgery, trauma or chronic ocular disease that may affect their vision\n4. Ocular or systemic medication use which may interfere or interact with myopia treatment or ocular development\n5. Child, parents or guardians not willing to comply with treatment and\u002For follow-up schedule and planning to migrate or move during the one-year study duration","4 Years","14 Years",{"count":137,"type":20},230,"12 Months","OBSERVATIONAL","Currently, optical and pharmacological interventions have been developed to prevent the progression of childhood myopia. However, no myopia control strategy has been shown to have complete efficacy in controlling myopia progression in children. One possible reason is that risk factors contributing to the development of myopia were not controlled in previous clinical studies including time outdoors and near vision behaviour. This study aims to quantify time spent outdoors and near vision behavior in myopic children and its impact on myopia control efficacy. The outcomes of this study will guide clinicians on risk management and improve responses to existing treatments for progressive myopia.",[142],"Myopia",[142,144,145,146,147,148,149],"Myopia control","Progressive myopia","Near vision behavior","Outdoor activity","Environment","Light exposure","2024-12-08",{"date":152,"type":31},"2024-12-12",{"date":154,"type":31},"2023-03-21",{"date":156,"type":20},"2026-12-31",{"name":37,"class":38},""]